

C. P. 3950 Lévis (Québec) G6V 8C6 desjardinslifeinsurance.com/planmember 1-844-410-6485

PRIOR AUTHORIZATION REQUEST

AMVUTTRA (VUTRISIRAN) ONPATTRO (PATISIRAN) TEGSEDI (INOTERSEN)

PLEASE READ THE INSTRUCTIONS ON THE BACK OF THIS FORM.

PATIENT IDENTIFICAT	ION – To be completed by the member.					
Patient's last and first name		Relationshi	p with member		Patient's date of birth	
		Member	Spouse	Dependent chil		
Member's last and first na	me	1	Contract No.		Certificate No.	
No., street, apt.	City				Province Postal code	
Telephone Nos – Home:	Office:	Exter	nsion:	Email:		
Since the response to this	request includes confidential information, please indicate	how you wou	ıld like to be inform	med of the decision:		
☐ By mail (The response	to your request will be sent to the address indicated in the	is section.)	☐ By fax:			
	s: If the patient has coverage under a private insurance a copy of the decision notice and this form filled out by t				an, please submit the request to this	
	Does the patient have drug coverage under a private	insurance pla	n?			
PRIVATE PLAN	Yes – Please provide a copy of the notice of appro-	val or refusal.	$ ightarrow$ \Box Copy	attached to this for	m.	
	Specify: Name of the insurer:		Contract No.	.:	Certificate No.:	
	No					
	Has a request for reimbursement been submitted un	der your prov	incial plan?			
PROVINCIAL PLAN	Yes – Please provide a copy of the notice of appro	val or refusal.	$ ightarrow$ \Box Copy	attached to this for	m.	
	No – Please explain:					
	Is the patient enrolled in a patient support program?	Yes] No			
PATIENT SUPPORT PROGRAM	If so – Program name:					
	Contact person:		Telephon	ne No.:	Extension:	
DECLARATION AND A	UTHORIZATION FOR THE COLLECTION AND CON	MMUNICAT	ION OF PERSON	NAL INFORMATIO	ON	
and insurance companies; when necessary use the pe	ecessary to manage my file. The non-exhaustive list of sou (b) communicate to the said persons or organizations only ersonal information it may have about me in existing files t oncerning my dependents, insofar as applicable to the clai	the personal hat are now cl	information about osed. This authoria	, t me that is deemed r zation is also valid fo	necessary for the purposes of my file; (c) r the collection, use and communication	
Signature of member:				Date:		
Last name and first name	of parent/legal guardian (if applicable):					
Signature of patient or parent/legal guardian (if applicable):			Date:			
CONSENT TO THE CO	MMUNICATION OF PERSONAL INFORMATION T	O A THIRD I	PARTY			
physician's medical team o	laim more efficiently, do you authorize Desjardins Insura of the reasons for the decision on your prior authorization		n the patient supp	port program and th	ne attending physician or the attending	
Yes No				Data		
Signature of member:				Date:		
Last name and first name	of parent/legal guardian (if applicable):					
	rent/legal guardian (if applicable):			Date:		
	N SECTION – To be completed by the attending physicial	1				
Physician's last and first na	me (PLEASE PRINT)	Lic	ense No.	Specialty		
No., street, suite	City	l		1	Province Postal code	
Telephone No.:		Fax No.:				
Signature of physician:				Date:		
Drug name	Formulation S	Strength	Dosage	Patient's weight	Scheduled duration of treatment	
Where is the drug adminis	tered? Home Physician's office P	rivate clinic	Hospital – Ir	npatient Hosp	oital – Outpatient	
	Other (please specify):					
425705 (2024 42)	Designations Insurance refers to Designation	c Financial C	ocurity Life Asset	ranco Company		

ATTENDING PHYSICIAN SECTION – Continued

- Make sure to fill out all sections so we can process the request faster. If any information is missing, we will send the form back to the member.
- In order to consider any diagnosis not mentioned on this form, we need supporting documents (clinical practice guidelines, clinical studies, etc.) that justify the drug's use in the given context.

DIAGNOSIS						
\square Polyneuropathy in adult with hereditary transthyretin-r	mediated amyloidosis (hATTR)					
Other therapeutic indication(s) – Please specify:						
INFORMATION RELATING TO POLYNEUROPATHY IN AI	DULT WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR)				
ienetic confirmation of hATTR: Yes No leuropathy Impairment score: <pre> < 5 points</pre>						
Does the patient exhibit severe heart failure symptoms de	fined as NYHA class III or IV?					
PRIOR MEDICATION OR TREATMENT Has the patient ever used medication or received treatme	nt for this medical condition? \square Yes \square No					
If not, please explain:	nent already received for this medical condition:					
is so, please list any medication already used of any treatment already received for this medical condition.						
MEDICATION OR TREATMENT NAME	OUTCOME	TREATMENT PERIOD				
Name:	Inefficiency Intolerance Contraindication	From:				
Dose:	Specify:	To:				
Name:	Inefficiency Intolerance Contraindication	From:				
Dose:	Specify:	To:				
Name:	Inefficiency Intolerance Contraindication	From:				
Dose:	Specify:	To:				
Name:	Inefficiency Intolerance Contraindication	From:				
Dose:	Specify:	To:				
PRESCRIPTION RENEWAL						
CURRENT Ambulatory condition: Stage 1 or 2 on the	Functional Ambulation Performance (FAP) scale					
Stage 1, 2, 3a or 3l	o on the Polyneuropathy Disability (PND) scale					
\Box Other, specify:						
INSTRUCTIONS – HOW TO COMPLETE AND RET	URN THIS FORM					
4. Constate and and D						

D

- Complete sections A and B.
- Ask your physician to complete section C. The member is responsible for assuming any costs incurred to complete this form or to obtain additional information. 2.
- To obtain a reimbursement once the drug has been approved, please use your payment card at the pharmacy or submit your original receipts by mail. Eligible drugs must be dispensed by a pharmacist or a physician, if there is no pharmacist.
- Send form: by fax: Designins Insurance

Group Insurance, Health Claims, 418-838-2134 or 1-877-838-2134 (toll-free) by mail: Desigrdins Insurance

Group Insurance, Health Claims C. P. 3950, Lévis (Québec) G6V 8C6

Under its prior authorization program, Desjardins Insurance authorizes the reimbursement of certain drugs that meet criteria that are based, in particular, on clinical practice guidelines and recommendations issued by health technology assessment organizations. The drug will be eligible for reimbursement if it meets the insurer's criteria, if it's not administered in a hospital and if it's not eligible under a government program. If the information on your form is complete, your request will normally be processed within 5 husiness days.

When the request form is received, it will be assessed in the strictest confidence. In some situations, additional diagnostic or clinical information may be required.

If the treatment continues beyond the authorized period, you will be asked to submit a new request form and provide information that justifies the extension of treatment. If you have a payment card, your pharmacist will be advised that the authorization period is coming to an end. The insurance must be in force and the patient still covered on the date expenses are incurred. This prior authorization is subject to change if, at the time expenses are incurred, the contract has been modified.

When Desjardins Insurance declines a prior authorization request, it is because we need to uphold conditions set out in the contract. It does not mean we are questioning the physician's opinion. If you have any questions, please contact our Customer Contact Centre at the number indicated on page 1 of this form.